Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population
Open accessAbstract
BACKGROUND: Significant anxiety symptoms are associated with poor clinical course and outcome in major depressive disorder (MDD). This single-arm, open-label study aimed to evaluate the efficacy and tolerability of escitalopram treatment in patients with MDD and anxiety symptoms. METHODS: Adult patients with MDD and anxiety symptoms (Montgomery-Asberg Depression Rating Scale [MADRS] ≥22 and Hamilton Anxiety Rating Scale [HAM-A] ≥14) were enrolled and received escitalopram (10-20 mg/day) treatment for 24 weeks. Symptom status was assessed by MADRS, 17-item-Hamilton Depression Rating Scale, HAM-A, and Clinical Global Impression Scale at baseline and the following visits. Quality of life was assessed by Short Form-12, and safety was evaluated by adverse events, laboratory investigations, vital signs, and physical findings. RESULTS: Overall, 200 of 318 (66.2%) enrolled patients completed the 24-week treatment. The remission (MADRS ≤10 and HAM-A ≤7) rate in the full analysis set (N=285) was 73.3% (95% confidence interval: 67.80, 78.38) at week 24. Mean (± standard deviation) MADRS total score was 33.4 (±7.13) and HAM-A score was 27.6 (±7.26) at baseline, which reduced to 6.6 (±10.18) and 6.0 (±8.39), respectively, at week 24. Patients with higher baseline depression and anxiety level took longer to achieve similar remission rates. Overall, 80 of the 302 (26.5%) patients included in the safety set reported at least 1 treatment-emergent adverse event (TEAE). Most frequently reported TEAEs (>2%) were headache (4.0%), nasopharyngitis (3.6%), nausea (3.0%), and dizziness (2.6%). Serious TEAEs were reported by 1.3% patients; no deaths were reported. CONCLUSION: Escitalopram 10-20 mg/day was effective and well-tolerated in the long-term treatment of MDD with anxiety symptoms in adult Chinese population.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Patients with anxious depression responded better to a single infusion of ketamine than those with nonanxious depression.
“Patients with anxious depression, however, responded better to a single infusion of ketamine than those with nonanxious depression [58].”
From Patients with anxious depression: overview of prevalence, pathophysiology and impact on course and treatment outcome (2018) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Diagnostic and Statistical Manual of Mental Disorders
(2012) · Springer eBooks · doi:10.1007/springerreference_121117 · Cited by 20,769 · see citing works
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · see citing works
Cross-Validation of Item Selection and Scoring for the SF-12 Health Survey in Nine Countries
Gandek, B., Ware, J. E., Aaronson, N. K., Apolone, G., Bjorner, J. B., Brazier, J. E., Bullinger, M., Kaasa, S., Leplege, A., Prieto, L., et al. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00109-7 · Cited by 2,907 · see citing works
The clinical global impressions scale: applying a research tool in clinical practice.
Busner, J., & Targum, S. D. (2007) · PubMed Central · Cited by 1,952 · see citing works
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654 · see citing works
Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)
Ma, F. (2020) · Springer eBooks · doi:10.1007/978-3-319-69892-2_419-2 · Cited by 1,241 · see citing works
Kessler, R. C., Nelson, C. B., McGonagle, K. A., Liu, J., Swartz, M. S., & Blazer, D. G. (1996) · The British Journal of Psychiatry · doi:10.1192/s0007125000298371 · Cited by 1,079 · see citing works
Fava, M., Rush, A. J., Alpert, J. E., Balasubramani, G. K., Wisniewski, S. R., Carmin, C. N., Biggs, M. M., Zisook, S., Leuchter, A., Howland, R., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111868 · Cited by 927 · see citing works
Kessler, R. C., DuPont, R. L., Berglund, P. A., & Wïttchen, H. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.12.1915 · Cited by 486 · see citing works
FAVA, M., ALPERT, J. E., CARMIN, C. N., WISNIEWSKI, S. R., TRIVEDI, M. H., BIGGS, M. M., SHORES-WILSON, K., MORGAN, D., SCHWARTZ, T., BALASUBRAMANI, G. K., et al. (2004) · Psychological Medicine · doi:10.1017/s0033291704002612 · Cited by 406 · see citing works
Fixed-Dose Trial of the Single Isomer SSRI Escitalopram in Depressed Outpatients
Burke, W. J., Gergel, I. P., & Bose, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0410 · Cited by 352 · see citing works
Arroll, B. (2005) · The Annals of Family Medicine · doi:10.1370/afm.349 · Cited by 351 · see citing works
Lepola, U. M., Loft, H., & Reines, E. H. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000074988.54339.7c · Cited by 254 · see citing works
Comorbid psychiatric disorders in depressed outpatients: Demographic and clinical features
Rush, A. J., Zimmerman, M. A., Wisniewski, S. R., D, M. F. M., Hollon, S. D., Warden, D., Biggs, M. M., Shores‐Wilson, K., Shelton, R. C., Luther, J. F., et al. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.03.005 · Cited by 252 · see citing works
BELZER, K., & SCHNEIER, F. R. (2004) · Journal of Psychiatric Practice · doi:10.1097/00131746-200409000-00003 · Cited by 235 · see citing works
Chen, Y. (2002) · Psychopathology · doi:10.1159/000065140 · Cited by 232 · see citing works
Gandek, Ware, Aaronson, & Apolone (1998) · Journal of Clinical Epidemiology · Cited by 225 · see citing works
Kennedy, S. H., Andersen, H. F., & Lam, R. W. M. (2006) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0615 · Cited by 216 · see citing works
Novick, J. S., Stewart, J. W., Wisniewski, S. R., Cook, I. A., Manev, R. M., Nierenberg, A. A., Rosenbaum, J. F., Shores‐Wilson, K., Balasubramani, G. K., Biggs, M. M., et al. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0807 · Cited by 211 · see citing works
Rating Scales in Mental Health
Sajatovic, M. (2012) · Johns Hopkins University Press eBooks · doi:10.56021/9781421406664 · Cited by 192 · see citing works
Frequency of Anxiety Disorders in Psychiatric Outpatients With Major Depressive Disorder
Zimmerman, M. A., McDermut, W., & Mattia, J. I. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.8.1337 · Cited by 191 · see citing works
Escitalopram versus other antidepressive agents for depression
Cipriani, A., Santilli, C., Furukawa, T. A., Signoretti, A., Nakagawa, A., McGuire, H., Churchill, R., & Barbui, C. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006532.pub2 · Cited by 190 · see citing works
Saveanu, R., Etkin, A., Duchemin, A.-M., Goldstein-Piekarski, A., Gyurak, A., Debattista, C., Schatzberg, A. F., Sood, S., Day, C. V. A., Palmer, D. M., et al. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.12.018 · Cited by 151 · see citing works
Waugh, J., & Goa, K. L. (2003) · CNS Drugs · doi:10.2165/00023210-200317050-00004 · Cited by 143 · see citing works
Defining anxious depression: a review of the literature
Ionescu, D. F., Niciu, M. J., Henter, I. D., & Zarate, C. A. (2013) · CNS Spectrums · doi:10.1017/s1092852913000114 · Cited by 119 · see citing works
Boulenger, J.-P., Huusom, A. K. T., Florea, I., Bækdal, T. A., & Sarchiapone, M. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x115513 · Cited by 112 · see citing works
Kirino, E. (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s22495 · Cited by 93 · see citing works
Anxiety and Depression: Optimizing Treatments
Ballenger, J. C. (2000) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v02n0301 · Cited by 83 · see citing works
Colonna, L., Andersen, H. F., & Reines, E. H. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x65484 · Cited by 82 · see citing works
Wu, Z., Chen, J., Yuan, C., Hong, W., Peng, D., Zhang, C., Cao, L., & Fang, Y. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.03.012 · Cited by 77 · see citing works
Estimation of Utilities for the Effects of Depression From the SF-12
Lenert, L. A., Sherbourne, C. D., Sugar, C. A., & Wells, K. B. (2000) · Medical Care · doi:10.1097/00005650-200007000-00008 · Cited by 63 · see citing works
Escitalopram versus venlafaxine XR in the treatment of depression
Montgomery, S., & Andersen, H. F. (2006) · International Clinical Psychopharmacology · doi:10.1097/00004850-200609000-00008 · Cited by 60 · see citing works
Baseline severity of depression predicts antidepressant drug response relative to escitalopram
Kilts, C. D., Wade, A. G., Andersen, H. F., & Schlaepfer, T. E. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902849258 · Cited by 58 · see citing works
Demyttenaere, K., Andersen, H. F., & Reines, E. H. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328303ac5f · Cited by 55 · see citing works
The cardiovascular safety profile of escitalopram
Thase, M. E., Larsen, K. G., Reines, E. H., & Kennedy, S. H. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.05.011 · Cited by 54 · see citing works
Cognitive therapy for anxious depression in STAR(*) D: what have we learned?
Farabaugh, A., Alpert, J., Wisniewski, S. R., Otto, M. W., Fava, M., Baer, L., Perlis, R., Friedman, E., Nyer, M., Bitran, S., et al. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.04.029 · Cited by 52 · see citing works
Woolley, S. B., Cardoni, A. A., & Goethe, J. W. (2009) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.12.1408 · Cited by 52 · see citing works
Escitalopram for the treatment of major depression and anxiety disorders
Höschl, C., & Švestka, J. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.4.537 · Cited by 50 · see citing works
Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder
Thase, M. E., Chen, D., Edwards, J., & Ruth, A. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000045 · Cited by 47 · see citing works
Structural Validation of the Hamilton Depression Rating Scale
Cole, J. C., Motivala, S. J., Dang, J., Lucko, A., Lang, N., Levin, M. J., Oxman, M. N., & Irwin, M. R. (2004) · Journal of Psychopathology and Behavioral Assessment · doi:10.1023/b:joba.0000045340.38371.04 · Cited by 44 · see citing works
Anxious versus non-anxious depression: difference in treatment outcome
Domschke, K., Deckert, J., Arolt, V., & Baune, B. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881108097723 · Cited by 42 · see citing works
Dahl, A. A., Ravindran, A. V., Allgulander, C., Kutcher, S., Austin, C., & Burt, T. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2005.00529.x · Cited by 39 · see citing works
Park, H. Y., Lee, B.-J., Kim, J., Bae, J. N., & Hahm, B. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.11.010 · Cited by 36 · see citing works
Mao, P., Tang, Y., Jiang, F., Shu, L., Gu, X., Li, M., Qian, M., Ma, C., Mitchell, P. B., & Cai, Z. (2006) · Depression and Anxiety · doi:10.1002/da.20222 · Cited by 35 · see citing works
Kornstein, S. G., Li, D., Mao, Y., Larsson, S., Andersen, H. F., & Papakostas, G. I. (2009) · CNS Spectrums · doi:10.1017/s1092852900020320 · Cited by 32 · see citing works
Mohamed, S., Osatuke, K., Aslam, M., & Kasckow, J. (2006) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2006.08.001 · Cited by 31 · see citing works
Improvement of Quality of Life in Panic Disorder with Escitalopram, Citalopram, or Placebo
Bandelow, B., Stein, D. J., Dolberg, O. T., Andersen, H., & Baldwin, D. S. (2007) · Pharmacopsychiatry · doi:10.1055/s-2007-984398 · Cited by 31 · see citing works
Boulenger, J.-P., Hermès, A., Huusom, A. K. T., & Weiller, E. (2010) · Current Medical Research and Opinion · doi:10.1185/03007990903482467 · Cited by 19 · see citing works
Efficacy of escitalopram monotherapy in the treatment of major depressive disorder
Li, G., Shen, Y., Luo, J., & Li, H. (2017) · Medicine · doi:10.1097/md.0000000000008142 · Cited by 19 · see citing works
Chatterjee, S., Maity, N., Ghosal, M. K., Gupta, A. N., Sil, A., & Chakraborty, S. (2014) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.135959 · Cited by 18 · see citing works
Dzevlan, A., Redzepagic, R., Hadzisalihovic, M., Curevac, A., Masic, E., Ališahović-Gelo, E., Merdzanovic, E., & Hadžimuratović, A. (2019) · Materia Socio Medica · doi:10.5455/msm.2019.31.14-18 · Cited by 18 · see citing works
Wang, G., You, X., Wang, X., Xu, X., Bai, L., Xie, J. M., Yao, Z., Yi, Q., Ma, J., Wang, J., et al. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s164673 · Cited by 11 · see citing works
Self-citationEfficacy of escitalopram oxalate for patients with post-stroke depression
Xu, J.-H., & Jiang, P. (2018) · Medicine · doi:10.1097/md.0000000000010219 · Cited by 5 · see citing works
Flagged first, then by citations
1 of the 54 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Gaspersz, R., Nawijn, L., Lamers, F., & Penninx, B. W. J. H. (2018) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000376 · Cited by 139 · see citing works
An update on the treatment of premature ejaculation: A systematic review
Saleh, R. A., Majzoub, A. A., & El‐Hamd, M. A. (2021) · Arab Journal of Urology · doi:10.1080/2090598x.2021.1943273 · Cited by 37 · see citing works
What is anxious depression? Overlap and agreement between different definitions
Zimmerman, M. A., Kerr, S., Kiefer, R., Balling, C. E., & Dalrymple, K. L. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.11.028 · Cited by 25 · see citing works
Efficacy of escitalopram monotherapy in the treatment of major depressive disorder
Li, G., Shen, Y., Luo, J., & Li, H. (2017) · Medicine · doi:10.1097/md.0000000000008142 · Cited by 19 · see citing works
Dzevlan, A., Redzepagic, R., Hadzisalihovic, M., Curevac, A., Masic, E., Ališahović-Gelo, E., Merdzanovic, E., & Hadžimuratović, A. (2019) · Materia Socio Medica · doi:10.5455/msm.2019.31.14-18 · Cited by 18 · see citing works
Firoozeei, T. S., Barekatain, M., Karimi, M., Zargaran, A., Akhondzadeh, S., & Rezaeizadeh, H. (2020) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2020.06.002 · Cited by 14 · see citing works
Khoo, Y., Demchenko, I., Frey, B., Milev, R., Ravindran, A., Parikh, S., Ho, K. T., Rotzinger, S., Lou, W., Lam, R. W., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.027 · Cited by 12 · see citing works
Ovlyakulov, B., Hu, B., Kan, H.-Y., Guo, Q., Li, X., Fan, H.-H., Wu, H., Wang, J., Zhang, X., & Zhu, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112715 · Cited by 11 · see citing works
Self-citationWang, G., You, X., Wang, X., Xu, X., Bai, L., Xie, J. M., Yao, Z., Yi, Q., Ma, J., Wang, J., et al. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s164673 · Cited by 11 · see citing works
Self-citationShen, Y., Zhao, Q., Yu, Y., Tan, Y., Zhang, H., Xu, X., Wang, Z., Li, Y., Hu, J., Zhong, J., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.07.023 · Cited by 9 · see citing works
Efficacy of escitalopram oxalate for patients with post-stroke depression
Xu, J.-H., & Jiang, P. (2018) · Medicine · doi:10.1097/md.0000000000010219 · Cited by 5 · see citing works
Dutt, R., Kamboj, S., & Kamboj, R. (2023) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2023.00741 · Cited by 5 · see citing works
Mahajan, S. S., Tandon, V. R., Arora, M., Mahajan, A., & Kotwal, S. K. (2019) · Journal of Mid-life Health · doi:10.4103/jmh.jmh_139_18 · Cited by 4 · see citing works
Hu, C., Yuan, G., Huang, H.-P., Liu, J.-W., Zhou, Y., Ren, Y., Li, Y., Tan, W.-J., Su, M.-L., & Zhou, Y. (2017) · Europe PMC (PubMed Central) · doi:10.3969/j.issn.1673-4254.2017.09.10 · Cited by 2 · see citing works
Self-citationKodali, M., Lella, S., Bodepudi, S., Benerji, T., & Parvathaneni, K. M. (2021) · IP Indian Journal of Neurosciences · doi:10.18231/j.ijn.2021.004 · Cited by 1 · see citing works
Mandal, T., Bairy, L. K., Sharma, P. S. V. N., & Valaparla, V. L. (2021) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-021-00302-7
Mahajan, S. S., Arora, M., Tandon, V., Mahajan, A., & Kotwal, S. K. (2022) · Journal of Mid-life Health · doi:10.4103/jmh.jmh_150_21
Clinical perspectives on the management of common psychiatric disorders in India
Reddy, M. S. S., Mohandas, E., Vaishnav, M., John, P., Kumar, S. S., Garg, U., Shah, B., & Das, J. (2022) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20222113
- Authors
- Jiang, K., Li, L., Xueyi, W., Fang, M., Shi, J., Cao, Q., He, J., Wang, J., Tan, W., & Hu, C.
- Affiliations
- Shanghai Mental Health Center (CN)
- Central South University (CN)
- Hebei Medical University (CN)
- Hangzhou Seventh Peoples Hospital (CN)
- Nanjing Drum Tower Hospital (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Xian Janssen Pharmaceutical Ltd. (China) (CN)
- Corresponding author
- Hu, Cuili
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2017-02
- Volume
- Volume 13
- Pages
- 515-526
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- PMC
- PMC5322850
- OpenAlex
- W2589019324
- Cited by
- 18
- References
- 54
- Citations by year
- 2024: 1 · 2023: 1 · 2022: 2 · 2021: 4 · 2020: 1 · 2019: 3 · 2018: 3 · 2017: 3
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Social Psychology › Mental Health Treatment and Access
- Keywords
- escitalopram, major depressive disorder, anxiety symptoms, comorbid depression and anxiety, antidepressant efficacy, tolerability, treatment-emergent adverse events, remission, Chinese patients, quality of life
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
